Arcturus Therapeutics Holdings Inc. (ARCT) Stock Price & Analysis

Arcturus Therapeutics Holdings Inc. (ARCT) rose 1.67% to USD 15.82 as of September 8, 2026 at 05:44 UTC, according to Nexqual real-time market data.

ARCT last closed at USD 15.82; the session ranged USD 15.4–16.02 on volume of 534,617 shares. Market capitalization is —, with a 52-week range of USD 5.5–24.17 (NGM). Source: Nexqual, September 8, 2026 at 05:44 UTC.

Key Statistics (as of September 8, 2026 at 05:44 UTC)

Technical Analysis (ARCT)

Nexqual's technical model rates ARCT "BUY" based on 5 bullish and 2 bearish signals across 128 daily candles, as of September 8, 2026 at 05:44 UTC.

From Arcturus Therapeutics Holdings Inc.'s Latest SEC 10-K Filing (filed 2026-03-03)

Key Strengths & Strategy (as disclosed to the SEC)

• In December 2022, we entered into a Collaboration and License Agreement ("CSL Collaboration Agreement") with CSL Seqirus, a part of CSL Limited and one of the world's leading influenza vaccine providers, for the global exclusive rights to research, develop, manufacture and commercialize self-amplifying mRNA vaccines against COVID-19, influenza and up to three other infectious diseases and global non-exclusive rights to pandemic pathogens.
• KOSTAIVE BLA Submission On September 5, 2025, the week prior to the planned Biologics License Application ("BLA") submission related to KOSTAIVE, the FDA requested that the submission of the BLA filing be delayed due to the FDA's expectation of providing additional advice.
• Our proprietary self-amplifying mRNA technology platform, or STARR ® ("STARR"), has been demonstrated to induce a robust, longer-lasting and broader humoral immune response at lower dose levels than conventional mRNA-based vaccines.
• Our proprietary LNP delivery system, LUNAR ® ("LUNAR"), is intended to address the major hurdle in RNA drug development, namely the effective and safe delivery of RNA to disease-relevant target tissues.

Partnerships

• In our vaccine program, we have partnered with CSL Seqirus, one of the world's leading influenza vaccine providers, on the development and commercialization of mRNA vaccines for COVID-19, influenza and three other infectious diseases.
• In our influenza vaccine franchise, a Phase 1 clinical trial of our seasonal influenza candidate was conducted in 2024-2025 under our collaboration with CSL Seqirus, and a BARDA-funded Phase 1 clinical trial of our H5N1 pandemic flu candidate was initiated in December 2024 and is ongoing.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 05:44 UTC. This page is informational and not investment advice.